Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
copanlisib + cisplatin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Combination of **copanlisib**, a potent reversible pan-class I phosphoinositide 3-kinase (PI3K) inhibitor with predominant activity against PI3K-α and PI3K-δ isoforms, plus **cisplatin** and **gemcitabine**, two standard cytotoxics. This regimen has been investigated for safety and efficacy in advanced solid tumors, especially biliary tract cancer (BTC) and cholangiocarcinoma. Copanlisib inhibits the PI3K/AKT pathway, supporting the hypothesis that this pathway’s blockade may sensitize tumors to DNA-damaging chemotherapy. Clinical studies evaluating this triple combination as first-line therapy in advanced BTC did not show improved survival over standard-of-care chemotherapy, although some objective responses were observed in early-phase trials. Copanlisib is developed by Bayer, and cisplatin/gemcitabine are established generics[1][2][3][4][5].
- Other names
- CisGem
02
Targets
PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CA (Phosphoinositide 3-kinase alpha)DNA
Beyond the preview
Go deeper on copanlisib + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on copanlisib + cisplatin + gemcitabine.